摘要 |
Carbamoyl tetrahydropyridine derivatives represented by the formula: [in the formula, R<SUP>1 </SUP>and R<SUP>2 </SUP>are identical or different, and each represents a hydrogen atom, a C<SUB>1</SUB>-C<SUB>5 </SUB>alkyl group, or the like; Y<SUP>1</SUP>-Y<SUP>2 </SUP>represents (R<SUP>4</SUP>)C-C(R<SUP>5</SUP>), (R<SUP>6</SUP>)C-N, N-N, (R<SUP>7</SUP>) N-CO, or N-C(R<SUP>8</SUP>); X<SUP>1</SUP>, X<SUP>2</SUP>, and X<SUP>3 </SUP>are identical or different, and each represents a hydrogen atom, a halogen atom, or the like; R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, and R<SUP>6 </SUP>are identical or different, and each represents a hydrogen atom or an alkyl group; R<SUP>7 </SUP>represents a hydrogen atom, a C<SUB>1</SUB>-C<SUB>5 </SUB>alkyl group, or the like; and R<SUP>8 </SUP>represents a hydrogen atom or a carbamoyl group] or a pharmaceutically acceptable salt thereof, and intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF.
|